Biotech Giant Gilead Sciences Goes on Sale
Gilead Sciences stock was selling for a mere 7 times estimated 2016 earnings when I snapped up 150 shares.

I’m pretty sure my reaction to big stock market swings is different from that of most other investors. When stocks are on a roll, as they were in 2013 and 2014, I get increasingly nervous. By the time most investors have reached a state of irrational exuberance, I’m practically paralyzed with fear. When the market slumps, as it did early this year, I become euphoric and immediately start dusting off my wish list of stocks that I want to own.
As a result, I’ve gone on a bit of a buying binge this year, snapping up shares of five companies for my Practical Investing portfolio. I already held two of them, Apple (symbol AAPL, $109) and American Capital (ACAS, $15), and added to my positions when I thought they had become too cheap. Since my recent purchases, Apple has gained 14% and American Capital has climbed 9%. (All share prices and returns are as of March 31.)
New additions to the portfolio this year are General Motors (GM, $31), Gilead Sciences (GILD, $92) and AV Homes (AVHI, $11). As I mentioned last month, I bought GM because I thought the stock, selling at 5.5 times projected 2016 earnings and paying a generous dividend, was too inexpensive to pass up. So far, so good. Including a dividend payment, I earned 11% on my GM purchase in a month.
From just $107.88 $24.99 for Kiplinger Personal Finance
Be a smarter, better informed investor.

Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
I bought the other two stocks for similar reasons: They’re good companies, and their stocks reside in the bargain basement. I’ll provide more details about AV Homes, the smallest firm in my portfolio, next month.
Gilead is not small. The world’s most valuable biotech company, with a market capitalization of $124 billion, Gilead has grown at a blistering clip in recent years. Revenues in 2015 soared 31% from the year before, and profits jumped a stunning 62%. The stock, however, was selling for a paltry 7 times estimated 2016 earnings when I snapped up 150 shares at $90.81 each.
Strangely, the remarkable success of Sovaldi and Harvoni, Gilead’s drugs for the treatment of hepatitis C, goes a long way toward explaining the stock’s absurdly low valuation. The hepatitis C virus—a blood-borne killer that can go undetected for years—is believed to affect as many as 5.2 million Americans. Harvoni, in particular, has a much higher success rate and fewer side effects than the drug cocktails that were used to treat hepatitis in the past.
Sovaldi and Harvoni are classic examples of what the drug industry calls blockbusters. They accounted for 60% of Gilead’s 2015 revenues of $32.6 billion. But the drugs have been so successful at curing hepatitis C that fewer patients are expected to need them. That, coupled with increased competition from other drugs, may suppress future sales and prices.
And speaking of drug prices, what Americans pay for meds has become a hot political issue. Lawmakers have criticized Gilead for the astronomical prices it charges for Harvoni and Sovaldi. That raises the specter of drug-price regulation, a serious threat for biotech companies.
Unfavorable ruling. Finally, a jury recently sided with Merck in a lawsuit that contended that Gilead infringed on two Merck patents related to a key ingredient in both hepatitis drugs. Gilead is appealing. But if the ruling stands, Gilead may need to pay royalties on past and future sales, which would likely cut into profits.
All of these factors are expected to stymie Gilead’s growth, at least temporarily. Analysts expect both sales and earnings to dip by 3% in 2016. But Gilead’s track record suggests that its days as one of the preeminent growth companies in health care are far from over. Gilead is developing other antiviral treatments and cancer drugs, and it has been a wise buyer of small firms that have promising products in development. Bottom line: At today’s valuation, Gilead is a risk worth taking.
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.

-
The Most Popular Apps for Retirement Planning in 2025
A J.D. Power survey ranks retirement planning apps based on customer service and satisfaction. Does your financial app make the cut?
-
Don't Disinherit Your Grandchildren: The Hidden Risks of Retirement Account Beneficiary Forms
Standard retirement account beneficiary forms may not be flexible enough to ensure your money passes to family members according to your wishes. Naming a trust as the contingent beneficiary can help avoid these issues. Here's how.
-
The Most Tax-Friendly States for Investing in 2025 (Hint: There Are Two)
State Taxes Living in one of these places could lower your 2025 investment taxes — especially if you invest in real estate.
-
The Final Countdown for Retirees with Investment Income
Retirement Tax Don’t assume Social Security withholding is enough. Some retirement income may require a quarterly estimated tax payment by the September 15 deadline.
-
S&P 500 Hits New High After Oracle Earnings: Stock Market Today
Another down day for Apple held the Dow Jones Industrial Average back, though.
-
Stocks Grind Up to New All-Time Highs: Stock Market Today
UnitedHealth stock led the Dow Jones Industrial Average amid increasing signs the labor market has not been well for months.
-
Markets Prepare for August Inflation Data: Stock Market Today
Apple CEO Tim Cook is still important, but price action this week is as much about incoming inflation data ahead of next week's Fed meeting.
-
Big Tech Names Rise Above Broad Weakness: Stock Market Today
Some familiar names enjoyed solid rallies on the resolution of outstanding questions, but macro uncertainty hangs over the broader market.
-
Tech Sells Off While Trump Stirs the Fed: Stock Market Today
We've reached another important part of earnings season, though markets remain captivated by the president, the Fed, and interest rate policy.
-
Dow Retreats From a Record High: Stock Market Today
Quietly rising since April, Home Depot stock was conspicuously constructive Tuesday as high-profile tech names dragged equity indexes down.